Phase I multiple ascending dose study of Z 944.
Latest Information Update: 09 Jan 2013
Price :
$35 *
At a glance
- Drugs Ulixacaltamide (Primary)
- Indications Pain
- Focus Adverse reactions
- 03 Jan 2013 Status changed from recruiting to completed, according to a Zalicus media release.
- 10 Jul 2012 Status changed from planning to recruiting, according to a Zalicus media release.
- 20 Jun 2012 New trial record